AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7629614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured mucosal grafts
Number of subjects: 8
Study 7629614 — intervention group
Group type: COMPARATOR
Intervention: Conventional split-thickness palatal graft
Number of subjects: 8
Study 2378424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 mg/kg)
Number of subjects: 24
Study 2378424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 319408 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclamid (3-6 tablets a day according to weight)
Number of subjects: 60
Study 319408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 319408 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclamid for 4 weeks followed by placebo for 4 weeks
Number of subjects: 60
Study 30973261 — intervention group
Group type: EXPERIMENTAL
Intervention: Messenger delivering bad news (innocent messenger)
Number of subjects: 11
Study 30973261 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire to sense-make activated
Number of subjects: 11
Study 30973261 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected bad news
Number of subjects: 11
Study 30973261 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of messenger's benevolence
Number of subjects: 11
Study 30973261 — intervention group
Group type: EXPERIMENTAL
Intervention: Messenger motives manipulated independently from news valence
Number of subjects: 11
Study 28870790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated WART
Number of subjects: 20
Study 25592171 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based estimation (insertion depth (cm) = weight (kg) + 6)
Number of subjects: 90
Study 25592171 — intervention group
Group type: COMPARATOR
Intervention: Gestation-based estimation (value determined from a table)
Number of subjects: 90
Study 23939537 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem sublingual tablet (ZST) 3.5 mg in fed state
Number of subjects: 100
Study 23939537 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem sublingual tablet (ZST) 3.5 mg in fasting state
Number of subjects: 100
Study 23939537 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem sublingual tablet (ZST) in fed state
Number of subjects: 100
Study 23939537 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem sublingual tablet (ZST) in fasting state
Number of subjects: 100
Study 21878080 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (Tricor) administered early (first 7 days) after myocardial revascularization
Number of subjects: 0
Study 18782333 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive semiannual dental care
Number of subjects: 534
Study 17298873 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention
Number of subjects: 281
Study 17298873 — intervention group
Group type: COMPARATOR
Intervention: No-intervention (control)
Number of subjects: 281
Study 15172773 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anaesthesia
Number of subjects: 2463
Study 15172773 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 2463
Study 11325573 — intervention group
Group type: EXPERIMENTAL
Intervention: 15D
Number of subjects: 397
Study 11325573 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 397
Study 11325573 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D and 15D
Number of subjects: 397
Study 9394077 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms t.d.s.)
Number of subjects: 12
Study 9394077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms t.d.s.)
Number of subjects: 12
Study 9394077 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 puffs t.d.s.)
Number of subjects: 12
Study 8529851 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 1091
Study 8529851 — intervention group
Group type: COMPARATOR
Intervention: Ex-smokers
Number of subjects: 1091
Study 8529851 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 1091
Study 8529851 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis
Number of subjects: 1091
Study 2371597 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil (5-FU) continuous regimen (5% cream applied nightly for 6 weeks)
Number of subjects: 49
Study 2371597 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil (5-FU) periodic regimen (5% cream applied 2 consecutive nights per week for 10 weeks)
Number of subjects: 49
Study 2371597 — intervention group
Group type: COMPARATOR
Intervention: Topical 5-fluorouracil (5-FU)
Number of subjects: 49
Study 345887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release ephedrine-theophylline-phenobarbital (ETP) tablet
Number of subjects: 20
Study 345887 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline tablets
Number of subjects: 20
Study 30204557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 7
Study 30204557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 7
Study 28841649 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sulphasalazine, methotrexate, hydroxychloroquine and low dose prednisolone (FIN-RACo DMARD combination)
Number of subjects: 99
Study 28841649 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab added on to the FIN-RACo DMARD combination
Number of subjects: 99
Study 28841649 — intervention group
Group type: COMPARATOR
Intervention: Placebo added on to the FIN-RACo DMARD combination
Number of subjects: 99
Study 24235105 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant GH (rhGH; n = 6)
Number of subjects: 12
Study 24235105 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plc; n = 6)
Number of subjects: 12
Study 21743344 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated preoperative education and counseling
Number of subjects: 40
Study 21246853 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild moxibustion for 10 minutes on each point, once every other day for 6 weeks
Number of subjects: 0
Study 21246853 — intervention group
Group type: COMPARATOR
Intervention: Mild moxibustion for 5 minutes
Number of subjects: 0
Study 21246853 — intervention group
Group type: COMPARATOR
Intervention: Mild moxibustion once every day
Number of subjects: 0
Study 21246853 — intervention group
Group type: COMPARATOR
Intervention: Mild moxibustion for 12 weeks
Number of subjects: 0
Study 18957613 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 at 0.33 ng.kg(‐1).min(‐1)
Number of subjects: 10
Study 18957613 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 at 0.66 ng.kg(‐1).min(‐1)
Number of subjects: 10
Study 18957613 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 at 2.0 ng.kg(‐1).min(‐1)
Number of subjects: 10
Study 18957613 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 15689903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoduct conductivity measuring sweat test system
Number of subjects: 111
Study 15689903 — intervention group
Group type: COMPARATOR
Intervention: Macroduct sweat collection system measuring chloride concentration
Number of subjects: 111
Study 12515749 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 72
Study 12515749 — intervention group
Group type: COMPARATOR
Intervention: Control (dietary therapy alone)
Number of subjects: 72
Study 9890856 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy for 2 months
Number of subjects: 32
Study 9890856 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 32
Study 7783051 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated gelatinase-B present in synovial fluids (SF)
Number of subjects: 138
Study 7783051 — intervention group
Group type: COMPARATOR
Intervention: No activated gelatinase-B in synovial fluids (SF)
Number of subjects: 138
Study 2296877 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose of oral anticoagulants (Group A)
Number of subjects: 60
Study 2296877 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 650 mg/day (Group B)
Number of subjects: 60
Study 2296877 — intervention group
Group type: COMPARATOR
Intervention: No antithrombotic therapy (Group C)
Number of subjects: 60
Study 6971092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg intravenous every 4 hours for 48 hours, followed by 1 g oral daily for 10 days)
Number of subjects: 88
Study 6971092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 31744452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (TXA)
Number of subjects: 40
Study 31744452 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 40
Study 30847561 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol 2 g plus 200 µg of folic acid (twice daily for 3 months)
Number of subjects: 150
Study 30847561 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg daily plus 200 µg of folic acid
Number of subjects: 150
Study 30847561 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 7.5 mg per day for 5 days (with folic acid)
Number of subjects: 150
Study 30847561 — intervention group
Group type: COMPARATOR
Intervention: Control group (200 µg of folic acid as placebo)
Number of subjects: 150
Study 28492910 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 362
Study 28492910 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept (2.0 mg)
Number of subjects: 362
Study 25574796 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise 5 d·wk(‐1) at 400 kcal per session
Number of subjects: 141
Study 25574796 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise 5 d·wk(‐1) at 600 kcal per session
Number of subjects: 141
Study 25574796 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 141
Study 25574796 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 141
Study 23338657 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine extended-release (ER) 45 mg s.i.d.
Number of subjects: 66
Study 23338657 — intervention group
Group type: COMPARATOR
Intervention: Propiverine immediate-release (IR) 15 mg t.i.d.
Number of subjects: 66
Study 21338987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 20μg/drospirenone 3mg
Number of subjects: 450
Study 21338987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 19728607 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive open reduction and internal fixation with improved compressing plate and screw
Number of subjects: 64
Study 19728607 — intervention group
Group type: COMPARATOR
Intervention: Standard AO plate via L-shaped incision
Number of subjects: 64
Study 17503974 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10, 15, 20, or 30 mg/day
Number of subjects: 1187
Study 17503974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1187
Study 15508561 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused reflection and articulation instruction
Number of subjects: 0
Study 15508561 — intervention group
Group type: COMPARATOR
Intervention: Control group (no focused reflection and articulation instruction)
Number of subjects: 0
Study 11816864 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 11816864 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 11816864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10406689 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents
Number of subjects: 0
Study 10406689 — intervention group
Group type: COMPARATOR
Intervention: Non-coated stents
Number of subjects: 0
Study 7524460 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (2 x 10(6) KIU in the pump prime solution)
Number of subjects: 40
Study 7524460 — intervention group
Group type: COMPARATOR
Intervention: Aspirin treatment
Number of subjects: 40
Study 3066983 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemithyl (actoprotective agent)
Number of subjects: 0
Study 3066983 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 29318985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell salvage
Number of subjects: 3028
Study 29318985 — intervention group
Group type: COMPARATOR
Intervention: Routine care without salvage
Number of subjects: 3028
Study 29318985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell salvage (emergency caesareans)
Number of subjects: 3028
Study 29318985 — intervention group
Group type: COMPARATOR
Intervention: Routine care without salvage (emergency caesareans)
Number of subjects: 3028
Study 29318985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell salvage (elective caesareans)
Number of subjects: 3028
Study 29318985 — intervention group
Group type: COMPARATOR
Intervention: Routine care without salvage (elective caesareans)
Number of subjects: 3028
Study 26586649 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 30
Study 26586649 — intervention group
Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 30
Study 26586649 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 24094768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg intravenously once every 2 weeks
Number of subjects: 355
Study 24094768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 24094768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 355
Study 22937831 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii 250 mg once a day
Number of subjects: 179
Study 22937831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no S. boulardii supplementation)
Number of subjects: 179
Study 20887413 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tidal volume (IV(T)) achieved by increasing the inspired plateau pressure 0.04 cmH(2)O/kg above the initial plateau pressure.
Number of subjects: 20
Study 20887413 — intervention group
Group type: COMPARATOR
Intervention: Normal tidal volume (NV(T)).
Number of subjects: 20
Study 18179503 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric home hospitalization service (GHHS)
Number of subjects: 104
Study 18179503 — intervention group
Group type: COMPARATOR
Intervention: General medical ward (GMW)
Number of subjects: 104
Study 17409822 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1100 mg/m on days 1 and 8) plus Carboplatin (AUC = 5 on day 8) every 28 days
Number of subjects: 100
Study 17409822 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m on days 1 and 8) plus Carboplatin (AUC = 5 on day 1) every 21 days
Number of subjects: 100
Study 12862346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptive Test/Clinical Linguistic and Auditory Milestone Scale (CAT/CLAMS)
Number of subjects: 0
Study 11099372 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (Cr; 5g, 4x/d for 4 days)
Number of subjects: 24
Study 8736419 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial physiotherapeutic treatment (OPT)
Number of subjects: 16
Study 8736419 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 1558439 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape seal applied to the catheter-drainage tubing junction
Number of subjects: 1740
Study 1558439 — intervention group
Group type: COMPARATOR
Intervention: No tape seal (control group)
Number of subjects: 1740
Study 3901535 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin (1 CU/kg/h, 0 to 120 min)
Number of subjects: 15
Study 3901535 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin and CCK (1 IU/kg/h, 60 to 120 min)
Number of subjects: 15
Study 3901535 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin and CCK
Number of subjects: 15
Study 31615181 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei Xiaoyao Powder (JWXYP)
Number of subjects: 180
Study 31615181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 28825508 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory specificity training (MEST)
Number of subjects: 66
Study 28825508 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review
Number of subjects: 66
Study 28825508 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 26066525 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (70 mg for 16 weeks)
Number of subjects: 24
Study 26066525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25274892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 3 synthetic disease-modifying antirheumatic drugs (sDMARD) and prednisolone (PRD), with infliximab or placebo infusions during the first 6 months
Number of subjects: 99
Study 23239968 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated subunit influenza A (H7N7) vaccine 7.5 µg
Number of subjects: 125
Study 23239968 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated subunit influenza A (H7N7) vaccine 15 µg
Number of subjects: 125
Study 23239968 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated subunit influenza A (H7N7) vaccine 45 µg
Number of subjects: 125
Study 23239968 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated subunit influenza A (H7N7) vaccine 90 µg
Number of subjects: 125
Study 23239968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 19882529 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium therapy (300 mg magnesium citrate for 1 month)
Number of subjects: 15
Study 19882529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 15
Study 17845256 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-WBC-reduced ABT
Number of subjects: 12
Study 17845256 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs or whole blood filtered after storage
Number of subjects: 12
Study 17845256 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestorage-filtered RBCs
Number of subjects: 12
Study 14705233 — intervention group
Group type: EXPERIMENTAL
Intervention: N of 1 trials with diclofenac 50 mg and misoprostol 200 microg twice a day for 2 weeks
Number of subjects: 51
Study 14705233 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (stopping NSAID and waiting)
Number of subjects: 51
Study 14705233 — intervention group
Group type: EXPERIMENTAL
Intervention: N of 1 trials with diclofenac
Number of subjects: 51
Study 14705233 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 51
Study 12085291 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) for plantar fasciitis
Number of subjects: 0
Study 12085291 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) for lateral elbow epicondylitis (tennis elbow)
Number of subjects: 0
Study 12085291 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) for calcifying tendinitis of the rotator cuff
Number of subjects: 0
Study 12085291 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled trials of ESWT
Number of subjects: 0
Study 9840847 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine/Epinephrine/Sufentanil/Clonidine (BESC)
Number of subjects: 100
Study 9840847 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine/Epinephrine/Clonidine (BEC)
Number of subjects: 100
Study 9840847 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine/Epinephrine/Sufentanil (BES)
Number of subjects: 100
Study 9840847 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine/Epinephrine (BE)
Number of subjects: 100
Study 8134190 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with calcium and phosphorus (enterally and/or parenterally)
Number of subjects: 74
Study 8134190 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control group)
Number of subjects: 74
Study 2510258 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil
Number of subjects: 12
Study 2510258 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 12
Study 29447737 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidity events before month 3 in SERAPHIN study
Number of subjects: 0
Study 29447737 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidity events before month 3 in GRIPHON study
Number of subjects: 0
Study 29447737 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidity events at 6-month and 12-month landmarks
Number of subjects: 0
Study 28668412 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcification (CAC) in 1, 2, and 3 vessels
Number of subjects: 1901
Study 28668412 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive calcification (CACSIS>5)
Number of subjects: 1901
Study 28668412 — intervention group
Group type: EXPERIMENTAL
Intervention: Major non-coronary atherosclerosis cardiovascular findings (NCACVF)
Number of subjects: 1901
Study 28668412 — intervention group
Group type: EXPERIMENTAL
Intervention: None or minimal NCACVF
Number of subjects: 1901
Study 28668412 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a predictor of death
Number of subjects: 1901
Study 28668412 — intervention group
Group type: EXPERIMENTAL
Intervention: History of malignancy as a predictor of death
Number of subjects: 1901
Study 28668412 — intervention group
Group type: EXPERIMENTAL
Intervention: NCACVF class as a predictor of death
Number of subjects: 1901
Study 28668412 — intervention group
Group type: EXPERIMENTAL
Intervention: CACSIS as a predictor of death among patients without malignancy
Number of subjects: 1901
Study 28668412 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 1901
Study 26248171 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session sexual risk reduction intervention
Number of subjects: 763
Study 26248171 — intervention group
Group type: COMPARATOR
Intervention: 8-session general health intervention (control)
Number of subjects: 763